- Home
- FRAF vs CTNM Comparison
FRAF vs CTNM Comparison
Compare FRAF & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FRAF
- CTNM
- Stock Information
- Founded
- FRAF 1906
- CTNM 2009
- Country
- FRAF United States
- CTNM United States
- Employees
- FRAF N/A
- CTNM N/A
- Industry
- FRAF Major Banks
- CTNM
- Sector
- FRAF Finance
- CTNM
- Exchange
- FRAF Nasdaq
- CTNM Nasdaq
- Market Cap
- FRAF 190.9M
- CTNM 174.6M
- IPO Year
- FRAF N/A
- CTNM 2024
- Fundamental
- Price
- FRAF $42.40
- CTNM $7.38
- Analyst Decision
- FRAF
- CTNM Strong Buy
- Analyst Count
- FRAF 0
- CTNM 4
- Target Price
- FRAF N/A
- CTNM $22.50
- AVG Volume (30 Days)
- FRAF 26.2K
- CTNM 196.1K
- Earning Date
- FRAF 07-22-2025
- CTNM 08-05-2025
- Dividend Yield
- FRAF 3.11%
- CTNM N/A
- EPS Growth
- FRAF 5.94
- CTNM N/A
- EPS
- FRAF 3.29
- CTNM N/A
- Revenue
- FRAF $74,998,000.00
- CTNM N/A
- Revenue This Year
- FRAF N/A
- CTNM N/A
- Revenue Next Year
- FRAF N/A
- CTNM N/A
- P/E Ratio
- FRAF $12.89
- CTNM N/A
- Revenue Growth
- FRAF 8.15
- CTNM N/A
- 52 Week Low
- FRAF $28.01
- CTNM $3.35
- 52 Week High
- FRAF $44.27
- CTNM $20.55
- Technical
- Relative Strength Index (RSI)
- FRAF 63.99
- CTNM N/A
- Support Level
- FRAF $38.52
- CTNM N/A
- Resistance Level
- FRAF $43.57
- CTNM N/A
- Average True Range (ATR)
- FRAF 1.15
- CTNM 0.00
- MACD
- FRAF 0.16
- CTNM 0.00
- Stochastic Oscillator
- FRAF 76.83
- CTNM 0.00
About FRAF Franklin Financial Services Corporation
Franklin Financial Services Corp is a bank holding company based in the United States. It is engaged in general commercial, retail banking and trust services normally associated with community banks. It offers a broad range of banking services to businesses, individuals and governmental entities which includes accepting and maintaining cheques, savings, and time deposit accounts, providing investment and trust services, making loans and providing safe deposit facilities. The bank also performs personal, corporate, pension and fiduciary services through its Investment and Trust Services Department.
About CTNM Contineum Therapeutics Inc. Class A Common Stock
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.